ARCHIVES
Case Report
Drug-Induced Maculopapular Rash Following Initiation of Anti-Tubercular Therapy: A Case Study
JaiGanesh Karthi Mahalingam1
Haripriya Gurumoorthy2
Jayasri Karthikesan3
Sivaraj Ravichandran4
Surya Rajendran5
1 Department of pulmonology, Government Medical College & hospital, Nagapattinam, Tamil Nadu, India. 2 3 4 5 Department of Pharmacy Practice, EGS Pillay College of Pharmacy, Nagapattinam, Tamil Nadu, India.
Published Online: September-October 2025
Pages: 95-98
Cite this article
↗ https://www.doi.org/10.59256/ijrtmr.20250505015
References
1. WHO. Treatment of Tuberculosis: Guidelines. 4th ed. World Health Organization; 2010.
2. Saukkonen JJ, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952.
3. Schaberg T, et al. Side effects of the antituberculosis drugs: Results of the German Thorax Center study. Eur Respir J. 1996;9(2):356–362.
4. Babalik A, et al. Management of cutaneous adverse drug reactions due to antituberculosis drugs. Int J Tuberc Lung Dis. 2012;16(6): 772–777.
5. Sharma SK, et al. Adverse reactions to anti-tuberculosis drugs & their management. Indian J Med Res. 2015;141(1):21–31.
6. Pirmohamed M, et al. Adverse drug reactions. BMJ. 2003; 329(7456): 15–19.
7. Yee D, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472–1477.
8. Chuenchom N, et al. Management of cutaneous adverse drug reactions due to antituberculosis drugs: A review. J Dermatolog Treat. 2020;31(3): 1–8.
9. Tostmann A, et al. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192–202.
10. WHO-UMC. The use of the WHO-UMC system for standardised case causality assessment. Uppsala Monitoring Centre; 2018.
2. Saukkonen JJ, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952.
3. Schaberg T, et al. Side effects of the antituberculosis drugs: Results of the German Thorax Center study. Eur Respir J. 1996;9(2):356–362.
4. Babalik A, et al. Management of cutaneous adverse drug reactions due to antituberculosis drugs. Int J Tuberc Lung Dis. 2012;16(6): 772–777.
5. Sharma SK, et al. Adverse reactions to anti-tuberculosis drugs & their management. Indian J Med Res. 2015;141(1):21–31.
6. Pirmohamed M, et al. Adverse drug reactions. BMJ. 2003; 329(7456): 15–19.
7. Yee D, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472–1477.
8. Chuenchom N, et al. Management of cutaneous adverse drug reactions due to antituberculosis drugs: A review. J Dermatolog Treat. 2020;31(3): 1–8.
9. Tostmann A, et al. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192–202.
10. WHO-UMC. The use of the WHO-UMC system for standardised case causality assessment. Uppsala Monitoring Centre; 2018.
Related Articles
2025
Exploring Mathematical Concepts in Ramcharit Manas: A Unique Perspective on Navadha Bhakti
2025
ARMOIRE An Augmented Reality Fashion Try On
2025
Sign Vision AI powered sign language Recognition
2025
Drowzy Alert AI Powered Driver Fatigue Detection
2025
Beauty Care Shopping using 3D Modelling
2025
